Yale tests magic mushroom compound for mental health
NCT ID NCT06442423
First seen Oct 31, 2025 · Last updated Jun 23, 2026 · Updated 26 times
Summary
This early-stage study at Yale University is testing whether a single 25 mg dose of psilocybin is safe and tolerable for people whose daily life is impaired by mood, anxiety, trauma, or addiction symptoms. Fifty adults will receive the drug in an open-label design (everyone knows they get it) and be followed for up to 12 months. The goal is to see if psilocybin can be given safely to a broad group of people with multiple mental health issues, not just one diagnosis.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANXIETY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Connecticut Mental Health Center - Yale School of Medicine
RECRUITINGNew Haven, Connecticut, 06519, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
psilocybin (a psychedelic compound found in certain mushrooms)
What this could lead to
If this trial shows psilocybin is safe and tolerable, it could pave the way for larger studies testing it as a treatment for a range of mental health conditions.
What could go wrong
This is a very early, small, open-label study with no placebo group, so results may not prove effectiveness. Psychedelics can cause intense psychological experiences and are not risk-free.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.